Research Services Division

Deakin Research

Research Output for John Reynolds

Note: The 2012, 2013, 2014 publications have not been audited.

Jump to: Publications | Grants and Consultancies | HDR completions

Publications

2013 Dean's Office HMNBS

Branford, Susan*, Yeung, David T.*, Ross, David M.*, Prime, Jodi A.*, Field, Chani R.*, Altamura, Haley K.*, Yeoman, Alexandra L.*, Georgievski, Jasmina*, Jamison, Bronte A.*, Phillis, Stuart*, Sullivan, Brad*, Briggs, Nancy E.*, Hertzberg, Mark*, Seymour, John F.*, Reynolds, John and Hughes, Timothy P.* (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML, Blood, vol. 121, no. 19, pp. 3818-3824, American Society of Hematology, Washington, D. C. [C1]
ERA journal ID: 15797 – Scopus EID: 2-s2.0-84880496470
Citation counts: Scopus - 11, Thomson - 11
DRO entry for this publication

Goodwill, Alicia M., Reynolds, John, Daly, Robin M. and Kidgell, Dawson J. (2013) Formation of cortical plasticity in older adults following tDCS and motor training, Frontiers in aging neuroscience, vol. 5, no. Article 87, pp. 1-9, Frontiers Research Foundation, Lausanne, Switzerland [C1]
ERA journal ID: Not matching ERA journal list
DRO entry for this publication

Miller, Clint T., Fraser, Steve F., Levinger, Itamar*, Straznicky, Nora E.*, Dixon, John B.*, Reynolds, John and Selig, Steve E. (2013) The effects of exercise training in addition to energy restriction on functional capacities and body composition in obese adults during weight loss : a systematic review, Plos one, vol. 8, no. 11, pp. 1-13, Public Library of Science, San Francisco, California [C1]
ERA journal ID: 39745 – Scopus EID: 2-s2.0-84896710963
Citation counts: Scopus - 1
DRO entry for this publication

2013 External

Jabbour, E.*, Le, Coutre P.D.*, Cortes, J.*, Giles, F.*, Bhalla, K.N.*, Pinilla-Ibarz, J.*, Larson, R.A.*, Gattermann, N.*, Ottmann, O.G.*, Hochhaus, A.*, Hughes, T.P.*, Saglio, G.*, Radich, J.P*, Kim, D-W.*, Martinelli, G.*, Reynolds, J.*, Woodman, R.C.*, Baccarani, M.* and Kantarjian, H.M.* (2013) Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance, Leukemia, vol. 27, no. 4, pp. 907-913, Nature Publishing Group, London, England [C1.1]
ERA journal ID: 16566 – Scopus EID: 2-s2.0-84876132746
Citation counts: Scopus - 4, Thomson - 5
DRO entry for this publication

2012 External

Iland, Harry J.*, Bradstock, Ken*, Supple, Shane*, Catalano, Alberto*, Collins, Marnie*, Hertzberg, Mark*, Browett, Peter*, Grigg, Andrew*, Firkin, Frank*, Hugman, Amanda*, Reynolds, John*, Di Iulio, Juliana*, Tiley, Campbell*, Taylor, Kerry*, Filshie, Robin*, Seldon, Michael*, Taper, John*, Szer, Jeff*, Moore, John*, Bashford, John* and Seymour, John* (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol. 120, no. 8, pp. 1570-1580, American Society of Hematology, Washington, D. C. [C1.1]
ERA journal ID: 15797 – Scopus EID: 2-s2.0-84865427746
Citation counts: Scopus - 42
DRO entry for this publication

Iland, Harry*, Bradstock, Ken*, Seymour, John*, Hertzberg, Mark*, Grigg, Andrew*, Taylor, Kerry*, Catalano, John*, Cannell, Paul*, Horvath, Noemi*, Deveridge, Sandra*, Browett, Peter*, Brighton, Tim*, Chong, Li*, Springall, Francisca*, Ayling, Juliet*, Catalano, Alberto*, Supple, Shane*, Collins, Marnie*, Di, Iulio Juliana* and Reynolds, John* (2012) Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia, Haematologica, vol. 97, no. 2, pp. 227-234, Ferrata Storti Foundation, Pavia, Italy [C1.1]
ERA journal ID: 16171 – Scopus EID: 2-s2.0-84856501661
Citation counts: Scopus - 13
DRO entry for this publication

Cervantes, C.*, Hughes, T.*, Etienne, G.*, De Souza, C.A.*, Dorlhiac Llacer, P.E.*, Schwarer, A.*, Leber, B.*, Lipton, J.*, Spector, N.*, Reynolds, J.*, Collins, L.*, Szczudlo, T.* and Rea, D.* (2012) Nilotinib induces deeper molecular responses vs continued imatinib in patients with ph+ chronic myeloid leukemia (CML) with detectable disease after ≥ 2 years on imatinib: ENESTcmr 12-months results, Haematologica, vol. 97, no. Supp 1, p. 239, Ferrata Storti Foundation, Pavia, Italy [C2.1]
ERA journal ID: 16171 – Scopus EID: Not tagged
DRO entry for this publication

Lipton, Jeffrey Howard*, Hughes, Timothy P.*, Leber, Brian*, De Souza, Carmino*, Dorlhiac-Llacer, Pedro E.*, Steegmann, Juan Luis*, Guerci-Bresler, Agnes*, Schwarer, Anthony P.*, Cervantes, Francisco*, Reynolds, John*, Collins, LaTonya R.*, Szczudlo, Tomasz K.* and Spector, Nelson* (2012) Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up, Journal of clinical oncology, vol. 30, no. 15, p. 1, American Society of Clinical Oncology, Alexandria, Va. [C2.1]
ERA journal ID: 16343 – Scopus EID: Not tagged
DRO entry for this publication

2011 External

Jefford, M.*, Mileshkin, L.*, Matthews, J.*, Raunow, H.*, O’Kane, C.*, Cavicchiolo, T.*, Brasier, H.*, Anderson, M.* and Reynolds, J.* (2011) Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem, Supportive care in cancer, vol. 19, no. 3, pp. 371-379, Springer Verlag, Berlin, Germany [C1.1]
ERA journal ID: 13803 – Scopus EID: 2-s2.0-79952252742
Citation counts: Scopus - 8, Thomson - 6
DRO entry for this publication

Wirth, Andrew*, Grigg, Andrew*, Wolf, Max*, Goldstein, David*, Johnson, Carol*, Davis, Sidney*, Dutu, Gaelle*, Kypreos, Poppy*, Smith, Carole*, Kneebone, Andrew*, Herzberg, Mark*, Joseph, David*, Catalano, John*, Roos, Daniel*, Stone, Janey* and Reynolds, John* (2011) Risk and response adapted therapy for early stage Hodgkin lymphoma : a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group / Trans-Tasman Radiation Oncology Group, Leukemia and lymphoma, vol. 52, no. 5, pp. 786-795, Informa Healthcare, London, England [C1.1]
ERA journal ID: 16567 – Scopus EID: 2-s2.0-79955061776
Citation counts: Scopus - 1, Thomson - 1
DRO entry for this publication

Hughes, Timothy P.*, Lipton, Jeffrey H.*, Leber, Brian*, Spector, Nelson*, Cervantes, Francisco*, Pasquini, Ricardo*, Clementino, Nelma*, Schwarer, Anthony P.*, Mahon, Francois-Xavier*, Rea, Delphine*, Yeung, David T.*, Kamel-Reid, Suzanne*, Bendit, Israel*, Reynolds, John*, Williams, Lisa*, Szczudlo, Tomasz* and Branford, Susan* (2011) Complete molecular response (CMR) rate With nilotinib in patients (pts) With chronic myeloid leukemia in chronic phase (CML-CP) without CMR after ≥ 2 Years on imatinib : preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice da, Blood, vol. 118, no. 21, p. 1, American Society of Hematology, Washington, D. C. [C2.1]
ERA journal ID: 15797 – Scopus EID: Not tagged
DRO entry for this publication

2010 External

Bayne, Michael*, Hicks, Rodney J.*, Everitt, Sarah*, Fimmell, Natalie*, Ball, David*, Reynolds, John*, Lau, Eddie*, Pitman, Alex*, Ware, Robert* and MacManus, Michael* (2010) Reproducibility of “intelligent” contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method, International journal of radiation oncology, biology, physics, vol. 77, no. 4, pp. 1151-1157, Elsevier, Amsterdam, The Netherlands [C1.1]
ERA journal ID: 16268 – Scopus EID: 2-s2.0-77953584001
Citation counts: Scopus - 22, Thomson - 18
DRO entry for this publication

Agrawal, Mridul*, Erben, Philipp*, Hanfstein, Benjamin*, Leitner, Armin*, Reynolds, John*, Woodman, Richard C.*, Robin, Laura*, Hofmann, Wolf-Karsten*, Hochhaus, Andreas* and Muller, Martin C.* (2010) Molecular predictors for the response to nilotinib treatment after acquired imatinib failure in ph+ chronic myeloid leukemia, Blood, vol. 116, no. 21, p. 1, American Society of Hematology, Washington, D. C. [C2.1]
ERA journal ID: 15797 – Scopus EID: Not tagged
DRO entry for this publication

Agrawal, M.*, Erben, P.*, Hanfstein, B.*, Popa, J.*, Hofmann, W.K.*, Reynolds, J.*, Robin, L.*, Leitner, A.*, Woodman, R.*, Hochhaus, A.* and Müller, M.* (2010) The predictive impact of MDR1 expression and pre-tumor burden on molecular, cytogenetic and clinical outcome of CML patients on nilotinib therapy after imatinib failure, Haematologica, vol. 95, no. Supp 2, pp. 58-59, Ferrata Storti Foundation, Pavia, Italy [C2.1]
ERA journal ID: 16171 – Scopus EID: Not tagged
DRO entry for this publication

Branford, Susan*, Martinelli, Giovanni*, Saglio, Giuseppe*, Kim, D.*, Shou, Y.*, Reynolds, John*, Woodman, Richard C.*, Kantarjian, H.*, Hochhaus, Andreas* and Radich, Jerald P.* (2010) Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients who fail imatinib, Journal of clinical oncology, vol. 28, no. 15, p. 1, American Society of Clinical Oncology, Alexandria, Va. [C2.1]
ERA journal ID: 16343 – Scopus EID: Not tagged
DRO entry for this publication

Hughes, T.*, Kim, D.*, Martinelli, G.*, Branford, S.*, Muller, M.C.*, Beppu, L.*, Goh, H.*, Soverini, S.*, Shou, Y.*, Reynolds, J.*, Woodman, R.*, Kantarjian, H.*, Saglio, G.*, Radich, J.* and Hochhaus, A.* (2010) Early molecular response to nilotinib in patients who failed imatinib is associated with a higher probability of cytogenetic response in chronic myeloid leukemia (CML), Haematologica, vol. 95, no. Supp 2, p. 54, Ferrata Storti Foundation, Pavia, Italy [C2.1]
ERA journal ID: 16171 – Scopus EID: Not tagged
DRO entry for this publication

Pasquini, Ricardo*, Cortes, Jorge*, Kantarjian, Hagop M.*, Joske, David*, Meillon, Luis*, Mongay, Lidia*, Reynolds, John*, Hughes, Timothy* and Kim, Dong-Wook* (2010) A worldwide observational registry collecting longitudinal data on management of chronic myeloid leukemia patients (the world CML registry) : 2nd annual interim analysis, Blood, vol. 116, no. 21, p. 1, American Society of Hematology, Washington, D. C. [C2.1]
ERA journal ID: 15797 – Scopus EID: Not tagged
DRO entry for this publication

2009 External

Kitessa, Soressa M.*, Williams, Andrew*, Gulati, Suresh*, Boghossian, Vivian*, Reynolds, John* and Pearce, Kelly L.* (2009) Influence of duration of supplementation with ruminally protected linseed oil on the fatty acid composition of feedlot lambs, Animal feed science and technology, vol. 151, no. 3 - 4, pp. 228-239, Elsevier, Amsterdam, The Netherlands [C1.1]
ERA journal ID: 5444 – Scopus EID: 2-s2.0-67349216178
Citation counts: Scopus - 5, Thomson - 6
DRO entry for this publication

Spencer, Andrew*, Prince, H. Miles*, Roberts, Andrew W.*, Prosser, Ian W.*, Bradstock, Kenneth F.*, Coyle, Luke*, Gill, Devinder S.*, Horvath, Noemi*, Reynolds, John* and Kennedy, Nola* (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure, Journal of clinical oncology, vol. 27, no. 11, pp. 1788-1793, American Society of Clinical Oncology, Alexandria, Va. [C1.1]
ERA journal ID: 16343 – Scopus EID: 2-s2.0-64649083365
Citation counts: Scopus - 181
DRO entry for this publication

Deininger, Michael*, O’Brien, Stephen G.*, Guilhot, Francois*, Goldman, John M.*, Hochhaus, Andreas*, Hughes, Timothy P.*, Radich, Jerald P.*, Hatfield, Alan K.*, Mone, Manisha*, Filian, Jeiry*, Reynolds, John*, Gathmann, Insa*, Larson, Richard A.* and Druker, Brian J.* (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib, Blood, vol. 114, no. 22, p. 1, American Society of Hematology, Washington, D. C. [C2.1]
ERA journal ID: 15797 – Scopus EID: Not tagged
DRO entry for this publication

Kim, Dong-Wook*, Granvil, Camille*, Demirhan, Eren*, Reynolds, John*, Jin, Yu*, Wang, Yanfeng*, Baccarani, Michele*, Cortes-Franco, Jorge*, Druker, Brian J.*, Hughes, Timothy P.* and Guilhot, Francois* (2009) Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with 400mg and 800mg daily doses of IM in the tyrosine kinase inhibi, Blood, vol. 114, no. 22, p. 1, American Society of Hematology, Washington, D. C. [C2.1]
ERA journal ID: 15797 – Scopus EID: Not tagged
DRO entry for this publication

Spencer, A.*, Prince, M.*, Roberts, A.*, Prosser, I.*, Bradstock, K.*, Coyle, L.*, Gill, D.*, Horvath, N.*, Reynolds, J.* and Kennedy, N.* (2009) Post-ASCT thalidomide consolidation further prolongs PFS for patients who have already achieved a complete remission, Clinical lymphoma myeloma, vol. 9, no. Supp 1, p. S35, Elsevier, Amsterdam, The Netherlands [C2.1]
ERA journal ID: 15928 – Scopus EID: Not tagged
DRO entry for this publication

2008 External

Everitt, S.J.*, Kron, T.*, Fimmell, N.*, Reynolds, J.*, Laferlita, C.*, Ball, D.*, Schneider-Kolsky, M.*, Budd, R.* and Mac, Manus M.P.* (2008) Interplanner variability in carrying out three-dimensional conformal radiation therapy for non-small-cell lung cancer, Journal of medical imaging and radiation oncology, vol. 52, no. 3, pp. 293-296, Wiley-Blackwell Publishing Asia, Melbourne, Vic. [C1.1]
ERA journal ID: 40470 – Scopus EID: 2-s2.0-43549094034
Citation counts: Scopus - 1
DRO entry for this publication

Hughes, Timothy P.*, Branford, Susan*, White, Deborah L.*, Reynolds, John*, Koelmeyer, Rachel*, Seymour, John F.*, Taylor, Kerry*, Arthur, Chris*, Schwarer, Anthony*, Morton, James*, Cooney, Julian*, Leahy, Michael F.*, Rowlings, Philip*, Catalano, John*, Hertzberg, Mark*, Filshie, Robin*, Mills, Anthony K.*, Fay, Keith*, Durrant, Simon*, Januszewic, Henry*, Joske, David*, Underhill, Craig*, Dunkley, Scott*, Lynch, Kevin* and Grigg, Andrew* (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy, Blood, vol. 112, no. 10, pp. 3965-3973, American Society of Hematology, Washington, D. C. [C1.1]
ERA journal ID: 15797 – Scopus EID: 2-s2.0-58149160055
Citation counts: Scopus - 94
DRO entry for this publication

Ross, Davi D. M.*, Grigg, Andrew*, Schwarer, Anthony*, Arthur, Christopher*, Loftus, Kerryn*, Mills, Anthony K.*, Filshie, Robin*, Columbus, Ruth*, Reynolds, John*, Seymour, John*, Branford, Susan* and Hughes, Timothy* (2008) The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early, Blood, vol. 112, no. 11, p. 1, American Society of Hematology, Washington, D. C. [C2.1]
ERA journal ID: 15797 – Scopus EID: Not tagged
DRO entry for this publication

Grants and Consultancies

All years

Research Income - National Competitive Grants

Smith, S, Short, M*, Saunders, S and Reynolds, J. Faecal Microbiota in Early Multiple Sclerosis, Multiple Sclerosis Research Australia Grant-In-Aid [T]

  • 2013: $24,800

Livingston, P, Osborne, R, Botti, M, Chirgwin, J*, Reynolds, J and Ashley, D. A Multi-Centre Randomised Controlled Trial to Test the Efficacy and Cost Effectiveness of an Intervention to Reduce Carer Burden and Depression among Caregivers of Cancer Patients., NHMRC Project Grant [T]

  • 2013: $182,391

Higher Degree by Research Completions supervised by John Reynolds

No completions found or audited.

Legend:
* Not a member of Deakin University at time of output.

DRO to publications collection last synchronised: Wednesday 17th September 2014 10:04pm

Deakin University acknowledges the traditional land owners of present campus sites.

23rd July 2011